Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy

J Nutr Health Aging. 2009 Apr;13(4):367-9. doi: 10.1007/s12603-009-0046-5.
No abstract available

MeSH terms

  • Alzheimer Disease / diagnostic imaging
  • Alzheimer Disease / drug therapy*
  • Biomarkers / analysis*
  • Biomarkers / metabolism
  • Clinical Trials, Phase II as Topic / methods
  • Humans
  • Randomized Controlled Trials as Topic
  • Research Design
  • Tomography, Emission-Computed, Single-Photon / methods*
  • tau Proteins / analysis*
  • tau Proteins / metabolism

Substances

  • Biomarkers
  • MAPT protein, human
  • tau Proteins